MNOV (MediciNova) Moat Score: 4/10 (As of Jun. 28, 2026)


MNOV MediciNova Inc MNOV
33 GF Score
Price $1.28
! 2 Warning Signs
View Full Analysis

What is MediciNova Moat Score?

MediciNova MNOV +0.53% 33 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates MNOV with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, MediciNova ranks better than 88.8% on this metric.

MediciNova has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

MediciNova has Narrow Moat: MediciNova Inc has a modest moat due to its intellectual property and ongoing R&D efforts in the biotech sector. However, the lack of significant market share and high competition in pharmaceuticals limit its moat strength. Regulatory barriers provide some protection but are not exclusive.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MediciNova might have Narrow Moat - Discernible but modest moat.

MediciNova  (NAS:MNOV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MediciNova Moat Score Related Terms

MNOV vs ENTX, IMA, ACRV: Moat Score Comparison

For the Biotechnology subindustry, MediciNova's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Moat Score distribution charts can be found below:

* The bar in red indicates where MediciNova's Moat Score falls into.


MNOV
33GF Score
MediciNova Inc MNOV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
MediciNova (MNOV) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MediciNova ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is MediciNova's Moat Score too high?
MediciNova's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. MediciNova's value of 4 is 100% above this industry median. Based on the distribution chart, MediciNova ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MediciNova has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Moat Score compare to ENTX and IMA?
According to the Biotechnology industry distribution chart, MediciNova ranks #157 out of 1402 companies for Moat Score. This places MediciNova in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. MediciNova's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediciNova's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediciNova's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. MediciNova's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MediciNova (MNOV), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges 4875:Japan
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
33GF Score

Get the complete analysis for MNOV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price